3 Under-the-Radar Stocks Flying Below Wall Street's Radar While Everyone Watches the War

The market is collectively losing its mind over geopolitical headlines, which is exactly when you should be scouring the corners of the tape for stocks nobody's talking about. Here are three genuinely obscure names worth your attention right now.

$CLDX (Celldex Therapeutics, ~$1.5B market cap) is a clinical-stage biotech developing antibody-drug conjugates and bispecific antibodies for hard-to-treat cancers. It's under the radar because it has no approved products yet — but its lead candidate barzolvolimab just posted jaw-dropping Phase 2 data in chronic urticaria, a condition affecting millions with no great treatment options. A Phase 3 readout is the catalyst that could reprice this stock overnight. Pure binary risk, but the science is legitimately exciting.

$LQDA (Liquidia Corporation, ~$800M market cap) makes a reformulated version of an existing pulmonary arterial hypertension drug using its proprietary PRINT particle engineering technology. The company won a key patent battle against United Therapeutics and is now in full commercial launch mode. Revenue is ramping, the TAM is enormous, and almost nobody outside of rare disease circles has heard of it.

Finally, $HRMY (Harmony Biosciences, ~$1.2B market cap) treats rare neurological sleep disorders like narcolepsy. It's profitable — actually profitable, not in a 'if you squint' way — generates real free cash flow, and trades at a steep discount to larger CNS peers. With a Bloomberg Podcasts segment this week highlighting the FDA's summer review of peptide drug restrictions and growing regulatory flexibility under RFK Jr., the broader specialty pharma and rare disease space is quietly getting a tailwind that most investors haven't priced in yet.

Three boring-sounding companies. Three very unboring potential outcomes. Sometimes the best plays are the ones that don't make the news ticker.